Drugs / GF-CART01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06703892 | Jun 2025 → Mar 2027 expected | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | GenomeFrontier Therapeutics TW Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-09-16 | GenomeFrontier Therapeutics TW Co., Ltd. | Results GF-CART01 Clinical Milestone & GF-CART03 Solid Tumor Innovation Unveiled genomefrontier.com ↗
Notably, the first patient achieved a Complete Metabolic Response (CMR) two months after CAR-T infusion, with imaging confirming complete tumor disappearance. |
| 2025-07-15 | GenomeFrontier Therapeutics TW Co., Ltd. | Results GenomeFrontier’s GF-CART01 Achieves Complete Response in First Patient of Phase I Trial, Demonstrating the Potential of the qCART™ platform genomefrontier.com ↗
The first patient treated with GF-CART01 achieved a complete metabolic response, as PET imaging showed no detectable tumor one month after the CAR T cell infusion. |
| 2025-02-11 | GenomeFrontier Therapeutics TW Co., Ltd. | Regulatory Taiwan FDA clears GenomeFrontier’s IND application for GF-CART01, a CD20/CD19 dual targeting CAR T cell therapy for hematological B cell malignancies! genomefrontier.com ↗
On February 6, 2025, the Taiwan Food and Drug Administration ( TFDA ) cleared its Investigational New Drug ( IND ) application for GF-CART01 , a CD20/CD19-directed dual targeting CAR T cell therapy for hematological B cell malignancies. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-16 | GenomeFrontier Therapeutics TW Co., Ltd. | GF-CART01 Clinical Milestone & GF-CART03 Solid Tumor Innovation Unveiled genomefrontier.com ↗ |
| 2025-07-15 | GenomeFrontier Therapeutics TW Co., Ltd. | GenomeFrontier’s GF-CART01 Achieves Complete Response in First Patient of Phase I Trial, Demonstrating the Potential of the qCART™ platform genomefrontier.com ↗ |
| 2025-05-05 | GenomeFrontier Therapeutics TW Co., Ltd. | GenomeFrontier Awarded $100,000 G-Rex® Grant to Advance Non-Viral CAR T Cell Therapy, GF-CART01 genomefrontier.com ↗ |
| 2025-02-11 | GenomeFrontier Therapeutics TW Co., Ltd. | Taiwan FDA clears GenomeFrontier’s IND application for GF-CART01, a CD20/CD19 dual targeting CAR T cell therapy for hematological B cell malignancies! genomefrontier.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GF-CART01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06703892 ↗ |
| Modality | Cell therapy | “GF- CART01 (CD20/19 CAR T Cell)” NCT06703892 ↗ |